Quick Takeaways:
- Zomedica has entered a strategic partnership with Veterinary Management Groups (VMG), making Zomedica a preferred provider for VMG’s network of 2,000+ veterinary members from September 2026 through August 2028.
- The partnership provides VMG members preferred access to Zomedica’s PulseVet shock wave therapy, Assisi tPEMF devices, VETIGEL hemostatic gel, TRUFORMA diagnostics and VETGuardian PLUS remote monitoring platform.
- The collaboration aims to expand access to point-of-care diagnostics, therapeutic technologies and remote monitoring, supporting clinical care and operational efficiency across independent veterinary practices.
Why It Matters?
Zomedica’s two‑year preferred‑provider partnership with Veterinary Management Groups (VMG) gives it structured access to more than 2,000 independent veterinary clinics (2,400+ practices) across the U.S., covering its full suite of diagnostics and therapeutics: PulseVet shockwave, Assisi tPEMF, VETIGEL, TRUFORMA point‑of‑care endocrine testing and VETGuardian PLUS remote monitoring. For Zomedica, which reports a >$2 billion U.S. addressable market for its current portfolio and 2025 revenue of $32 million (up 17% YoY), the VMG channel can accelerate adoption of higher‑value devices and assays in independent practices, while VMG members gain preferred terms on technologies aimed at improving clinical outcomes and operational efficiency.
Source: AccessNewswire
